8-K: BioXcel Stockholders Approve Reverse Split, Elect Directors

BioXcel Therapeutics, Inc. stockholders approved a reverse stock split proposal and elected three Class I directors at their annual meeting on December 12, 2025.

Summary

• The Annual Meeting of stockholders was held on December 12, 2025, with 9,726,849 shares (approximately 44.68% of outstanding common stock) present or represented by proxy.
• Three Class I directors, June Bray, Sandeep Laumas, M.D., and David Mack, were elected for terms expiring at the 2028 annual meeting.
• The appointment of Ernst & Young LLP as the independent registered public accounting firm for the year ending December 31, 2025, was ratified with 9,478,711 votes FOR.
• Stockholders provided advisory (non-binding) approval of the compensation of named executive officers with 1,616,305 votes FOR.
• An amendment to the Amended and Restated Certificate of Incorporation was approved, authorizing the Board to effect a reverse stock split at a ratio of 1-for-2 to 1-for-20 within 12 months to regain compliance with Nasdaq's minimum bid price requirements, receiving 7,557,091 votes FOR.
• Authorization for one or more adjournments of the Annual Meeting to solicit additional proxies for the reverse stock split proposal was also approved, but was not necessary as the proposal passed.

Sentiment

Score: 4

Explanation: The approval of all proposals, including the critical reverse stock split, is a necessary step to address compliance issues. However, the underlying reason for the reverse split (Nasdaq minimum bid price non-compliance) and significant 'against' votes for it indicate ongoing challenges and some stockholder concern, preventing a higher score.

Positives

• All five proposals presented at the Annual Meeting were approved by stockholders, indicating support for the company's governance and strategic direction.
• The approval of the reverse stock split amendment provides the Board with the necessary authority to address Nasdaq minimum bid price compliance, a critical step for maintaining listing.
• The election of three Class I directors ensures continuity in board leadership and oversight.
• The ratification of Ernst & Young LLP as the independent auditor maintains robust financial oversight and compliance.

Negatives

• A significant number of broker non-votes (7,668,937) were recorded for director elections and the executive compensation advisory vote, suggesting a lack of active participation from a large portion of shares held in street name.
• A substantial number of votes (2,116,237) were cast AGAINST the reverse stock split proposal, indicating notable stockholder opposition to this measure.
• The necessity of proposing a reverse stock split highlights an underlying issue with the company's stock price failing to meet Nasdaq's minimum bid price requirements.

Risks

• The company faces the risk of potential delisting from The Nasdaq Capital Market if it fails to regain compliance with the minimum bid price requirements, which the reverse stock split is intended to address.
• While approved, the implementation of a reverse stock split does not guarantee long-term compliance with Nasdaq requirements or a sustained improvement in stock performance.
• Significant stockholder opposition to the reverse stock split (2,116,237 votes AGAINST) could reflect broader concerns about the company's strategy or valuation.

Future Outlook

The Board of Directors has been authorized to effect a reverse stock split within 12 months following stockholder approval, if deemed necessary and advisable, to regain compliance with Nasdaq's minimum bid price requirements. This action is a forward-looking measure to maintain the company's listing.

Industry Context

This announcement primarily concerns corporate governance and compliance matters specific to BioXcel Therapeutics, Inc. and does not provide direct insights into broader industry trends or competitive landscape.

Management Changes

Corporate Governance

Stakeholder Impact

• **Shareholders**: Directly impacted by the election of directors and the potential reverse stock split, which could affect the number of shares held and the per-share price. The reverse split is intended to maintain Nasdaq listing, which benefits shareholders by ensuring market liquidity.
• **Management/Board**: The Board now has the explicit authority to implement a reverse stock split to address compliance issues, providing a clear path forward for maintaining listing.
• **Regulatory Bodies**: The company is taking steps to address compliance with Nasdaq listing requirements, which is a positive signal to regulatory authorities.

Next Steps

• The Board of Directors will determine if and when to effect the approved reverse stock split within 12 months to regain Nasdaq compliance, if deemed necessary and advisable.

Key Dates

Keywords

BioXcel Therapeutics, BTAI, SEC filing, 8-K, annual meeting, stockholder vote, director election, corporate governance, reverse stock split, Nasdaq compliance, executive compensation, auditor ratification